Development and validation of a methotrexate adherence assay

BACKGROUND: The first-line therapy for rheumatoid arthritis (RA) is weekly oral methotrexate (MTX) at low dosages (7.5–25 mg/week). However, ~40% of patients are non-adherent which may explain why some do not respond and need to start more expensive biological therapies. To monitor adherence more ac...

Full description

Saved in:
Bibliographic Details
Published in:Ann Rheum Dis
Main Authors: Bluett, James, Riba-Garcia, Isabel, Verstappen, Suzanne M M, Wendling, Thierry, Ogungbenro, Kayode, Unwin, Richard D, Barton, Anne
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2019
Subjects:
Rheumatoid Arthritis
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788879/
https://ncbi.nlm.nih.gov/pubmed/31167761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-215446
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items